



SKIN CANCER (OTHER THAN MELANOMA)

CEPHALIC TUMOR REVEALING SYSTEMIC B-CELL LYMPHOMA

Sara Oukarfi⁽¹⁾ - Hanane Baybay⁽¹⁾ - Sara Elloudi⁽¹⁾ - Fatima Zahra Mernissi⁽¹⁾

Hospital University Hassan 2, Dermatology, Fes, Morocco⁽¹⁾

Background: Primary cutaneous Centro-follicular B-cell lymphoma (LBCCF) is an indolent lymphoma, lesions are most often located on the scalp, forehead or trunk.

We report the case of a patient with systemic follicular B-cell lymphoma revealed by a frontal lesion.

Observation: A 51 years old, has presented for the last year an asymmetric erythematous tumor of 8 cm diameter, well-defined with irregular contours, with mamillated surface and infiltrated base, sitting at the forehead, with a right cervical lymphadenopathy. The rest of the clinical examination was normal. Histology was compatible with an LBCCF inviting to look for a secondary localization to retain a primitive.

A lymph node ultrasonography showed a mandibular lymphadenopathy of malignant appearance, biopsy confirmed a secondary localization. A CTAP scanner showed parotid lymphadenopathy with no other secondary localization. B2 micro globulin and LDH were slightly elevated.

We retained the diagnosis of systemic centro follicular B-lymphoma and the patient received a poly-chemotherapy, currently in remission with a follow-up of 18 months.

Key message: Usually, primary or secondary cutaneous follicular B lymphoma lesions are characterized by infiltrated erythematous nodules distributed asymmetrically on the cephalic extremity, less often on the trunk.

In our case, the patient had a cutaneous involvement with concomitant lymph node involvement, which allowed the diagnosis to be made. Nevertheless, the positivity of bcl-2 and the histological confirmation of ganglionic lymphomatous involvement led to secondary lesions. Systemic and primary cutaneous B lymphoma are two different entities. LBCCF has a better rate of treatment responses and a better prognosis, and therefore do not require, in the majority of cases, heavy chemotherapy treatments. The expression of bcl-2 in a cutaneous LBCC should therefore encourage us to look for a systemic lymphoma with secondary cutaneous involvement.

